Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.8K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K
Lineage Commitment01:21

Lineage Commitment

4.5K
Commitment is the  process whereby stem cells:
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disappearance of the Defining Organized Ultrastructural Lesion in Chronic Lymphocytic Leukemia-Associated Monoclonal Immunotactoid Glomerulopathy After Ibrutinib Therapy.

Kidney international reports·2026
Same author

Prognostic impact of KMT2A-PTD in acute myeloid leukemia in the NGS era: a multicenter retrospective study.

Annals of hematology·2026
Same author

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial.

Blood cancer journal·2026
Same author

Osteopontin from monocyte-derived dendritic cells mediates ozone-induced pulmonary responses in mice.

Frontiers in immunology·2026
Same author

Feasibility of Salvage Therapy With High-Dose Bendamustine and Rituximab Based on a Series of Two Cases From a Planned Phase II Trial for Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Cureus·2026
Same author

Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan.

International journal of hematology·2026

Related Experiment Video

Updated: Mar 6, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

871

[Key points in selecting first-line therapy for chronic myeloid leukemia].

Shinya Kimura1

  • 1Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|March 4, 2026
PubMed
Summary

Treatment for chronic myeloid leukemia (CML) involves selecting the best tyrosine kinase inhibitor (TKI) based on individual patient factors. The goal is shifting towards treatment-free remission (TFR) and potential cures.

Keywords:
Chronic myeloid leukemiaFirst lineSTAMP inhibitorTyrosine kinase inhibitor

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.8K

Related Experiment Videos

Last Updated: Mar 6, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

871
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.8K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Chronic myeloid leukemia (CML) is driven by the BCR::ABL1 fusion gene.
  • Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, significantly improving survival.
  • Five TKIs are approved for first-line therapy in Japan, each with unique profiles.

Purpose of the Study:

  • To review current evidence and practical considerations for selecting first-line TKI therapy in chronic-phase CML.
  • To discuss optimizing long-term outcomes and advancing towards individualized treatment strategies.
  • To explore emerging goals such as treatment-free remission (TFR) and potential curative approaches.

Main Methods:

  • Review of current clinical trial data and evidence for first-line TKIs in CML.
  • Analysis of distinct efficacy and toxicity profiles of approved agents.
  • Consideration of patient-specific factors influencing treatment decisions.

Main Results:

  • Individualized treatment selection is crucial, considering age, comorbidities, cardiovascular risk, fertility, adherence, and financial factors.
  • Treatment goals are evolving from disease control to achieving treatment-free remission (TFR).
  • Low-dose and step-up TKI regimens aim to balance efficacy with tolerability and quality of life.

Conclusions:

  • Optimizing first-line TKI selection is key for long-term CML management.
  • Future directions include exploring immunologic determinants of TFR and novel stem cell-targeting therapies for potential cures.
  • Personalized medicine approaches are advancing CML treatment towards improved outcomes and remission.